Selank as a Tuftsin Analogue: What Animal Studies Report

Selank is described in the published literature as a synthetic analogue of tuftsin, the endogenous immunoregulatory tetrapeptide, and has been examined for transcriptional effects on immune-related genes as well as for behavioural effects in rodents [1][2]. The retrieved study set is composed entirely of animal work; none of these reports characterise direct receptor binding or receptor occupancy for Selank, so any receptor-level interpretation is not supported by the studies summarised here [1][2][3][4]. In mice, a single intraperitoneal administration of Selank was followed by measurable changes in the expression of genes involved in inflammatory signalling in the spleen [2]. In that animal experiment, 84 inflammation-associated transcripts — including chemokines, cytokines and their receptors — were profiled by real-time PCR at 6 and 24 h, and significant expression changes were reported for 34 of them [2]. The authors highlighted Bcl6, a transcriptional repressor they describe as central to immune system formation and development, as showing significant expression changes after injection of Selank and of each of the tested peptide fragments, together with changes in Bcl6 target and corepressor genes [2]. A related animal report followed the time course of individual transcripts rather than a broad panel [1]. In mouse spleen, the C3 mRNA level was reported to fall approximately three-fold by 30 min after Selank administration, with a comparable change after administration of the short fragment Gly-Pro [1]. The same study described a wave-like pattern in Casp1 mRNA after Selank, early-timepoint changes in Il2rg mRNA after both Selank and Gly-Pro, and a similar reduction in Xcr1 mRNA at 90 min for the full peptide and the dipeptide [1]. Because the expression profiles of Selank and Gly-Pro coincided in most cases, the authors proposed that the dipeptide contributes actively to the overall transcriptional response attributed to Selank [1]. A further animal report on chemokine, cytokine and receptor gene expression in mouse spleen at 6 and 24 h likewise found that changes produced by the full peptide were largely reproduced by Gly-Pro, which that report identifies as a Selank fragment previously associated with antiviral activity [3]. Outside the immune-gene literature, an earlier rat study compared tuftsin (Thr-Lys-Pro-Arg) with its analogue TP-7 (Thr-Lys-Pro-Arg-Pro-Gly-Pro), the heptapeptide sequence corresponding to Selank, in 95 adult male Wistar rats that had received neonatal 5,7-dihydroxytryptamine to produce chronic deprivation of serotonergic system activity [4]. In that animal model, intracutaneous administration of either peptide was reported to weaken the animals' perception of stress situations, increase the stability of investigative behaviour, and normalise brain serotonin levels; the authors characterised the anxiolytic and psychostimulant activity of TP-7 as more pronounced than that of tuftsin [4]. Taken together, the retrieved studies situate Selank as a tuftsin-derived peptide studied in rodents at two levels: transcriptional readouts of inflammation-related genes in mouse spleen [1][2][3] and behavioural plus neurochemical readouts in a serotonin-lesioned rat model [4]. All findings above are preclinical, and none of the four reports includes human data or receptor-binding measurements [1][2][3][4].